Table 1.

Patient demographic data, disease activity scores (DAS28), and fatigue scores (FACIT fatigue)

Patient number	Age (years)	Rheumatoid factor status	Disease duration (years)	Concurrent DMARD	Concurrent corticosteroid NSAID or COX2	DAS 28 pre-adalimumab	DAS 28 after 3 months of adalimumab	FACIT fatigue pre-adalimumab	FACIT fatigue after 3 months of adalimumab
1	49	+	13	leflunomide	diclofenac	7.38	2.84	15	33
2	43	+	7	none	celecoxib	7.42	3.88	2	46
3	57	-	14	Methotrexate leflunomide	celecoxib	6.37	3.41	22	45
4	60	+	4	none	celecoxib	6.32	2.59	46	44
5	44	-	9	none	none	6.36	4.36	9	25
6	37	+	17	methotrexate	naproxen	6.33	4.50	11	20
7	39	+	13	methotrexate	diclofenac	6.56	3.53	17	43
8	39	-	18	methotrexate	indomethacin	6.25	4.46	25	33
9	61	-	12	none	none	6.01	2.16	26	47
10	52	-	12	sulfasalazine	none	7.37	2.95	18	39
11	49	-	13	methotrexate	none	6.29	5.41	16	36
12	53	+	10	leflunomide	diclofenac	8.20	4.49	15	24
13	53	+	13	none	none	5.11	5.11	40	41

COX2, Cyclooxygenase-2 inhibitor; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug.